Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002087 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
A Phase 1 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002087: Completed Phase 1 study, sponsored by Pharmacia and Upjohn.
NCT00002087 is a Phase 1 study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002087, a Phase 1 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels.
Interventions
- DRUG Alvircept sudotox
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002087
The ClinicalTrials.gov registry entry for NCT00002087 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alvircept sudotox is the first listed.
NCT00002087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002087 about?
NCT00002087 is a clinical study titled "Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals". To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte...
What is the current status of trial NCT00002087?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002087?
The interventions under investigation include: Alvircept sudotox (DRUG).
Who is sponsoring clinical trial NCT00002087?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.